Cost & Access
May 13, 2026 • 9 min read
Ozempic's list price is $935/month—but that number is almost irrelevant to what you'll actually pay. The Novo Nordisk Savings Card gets commercially insured patients to $25/month. NovoCare Patient Assistance covers uninsured income-qualified patients at $99/month. GoodRx barely helps. Here's the decision tree for your specific situation, including the critical distinction between Ozempic (Type 2 diabetes) and Wegovy (weight management).
Read the full guide →
Drug Comparison
May 13, 2026 • 11 min read
Four brand names, two molecules. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. The SURMOUNT-5 head-to-head trial settled the efficacy debate: tirzepatide produced 20.2% average weight loss vs 13.7% for semaglutide. We break down mechanism differences, side effect profiles, cost comparisons (including Zepbound's $399/month vial option), and who should consider which drug.
Read the full guide →
Eligibility
May 13, 2026 • 10 min read
FDA criteria require a BMI ≥ 30, or ≥ 27 with a weight-related comorbidity (hypertension, sleep apnea, high cholesterol, and others). But insurance applies stricter requirements: prior authorization, step therapy, formal comorbidity documentation. Medicare covers GLP-1s for Type 2 diabetes but not weight loss (with a narrow Zepbound exception for sleep apnea). This guide covers the full picture—and when the telehealth pathway makes sense.
Read the full guide →
Results & Expectations
May 13, 2026 • 10 min read
STEP-1 averaged 14.9% weight loss for semaglutide. SURMOUNT-1 averaged 20.9% for tirzepatide. But the distributions matter: about 1 in 6 semaglutide patients lost less than 5%, while 1 in 3 lost over 20%. We explain what predicts response, when results peak (months 16-18), the critical regain data (two-thirds of weight returns within one year of stopping), and how to protect muscle mass during treatment.
Read the full guide →
Compounding
May 13, 2026 • 10 min read
The FDA removed semaglutide from the drug shortage list in 2025, ending the legal window that allowed 503A pharmacies to compound it freely. This guide explains exactly what changed, what remains legally available through 503B outsourcing facilities, how telehealth companies pivoted, the real quality risks (semaglutide sodium vs. free base, dosing variability, sterility), and how to evaluate a compounding pharmacy if you're still considering this route.
Read the full guide →
Insurance & Cost
Sep 1, 2025 • 10 min read
Medicare covers Ozempic for Type 2 diabetes but not weight loss. Most commercial plans cover it for T2D with prior auth. Wegovy coverage for weight management depends on your plan. We break down every insurance type, the prior authorization process, step therapy requirements, and exactly how to appeal a denial—with a 30–40% overturn rate on appeal, it's worth pursuing.
Read the full guide →
Side Effects
Sep 1, 2025 • 11 min read
Nausea peaks in weeks 2–4 after each dose increase, then fades as your body adapts. This week-by-week guide covers the full Ozempic titration schedule (0.25mg → 2mg), what to expect at each stage, evidence-based strategies for managing GI side effects, the real story on hair loss, injection site reactions, and the serious warning signs—pancreatitis, retinopathy, thyroid—that require immediate attention.
Read the full guide →
Cost & Access
Sep 1, 2025 • 10 min read
NovoCare Patient Assistance provides brand-name Ozempic/Wegovy for $99/month to uninsured income-qualified patients. Telehealth subscriptions offer compounded semaglutide at $150–$300/month without insurance. We walk through every pathway—manufacturer assistance, telehealth, compounding, and more—with eligibility requirements, realistic costs, and how to get a prescription fast.
Read the full guide →
Drug Comparison
Sep 1, 2025 • 9 min read
Both contain semaglutide—but they have different FDA indications, max doses (2mg vs. 2.4mg), titration schedules, and insurance coverage rules. Using the wrong one for your indication means denied claims. We break down every meaningful difference and explain when each is the appropriate prescription for your situation.
Read the full guide →
Lifestyle
Sep 1, 2025 • 10 min read
GLP-1 medications slow gastric emptying—changing how alcohol is absorbed and increasing its effects. But the more interesting story is why so many patients spontaneously drink less: GLP-1 receptors in the brain's reward system modulate cravings for alcohol just as they modulate food cravings. We cover safety, the emerging research on GLP-1s and alcohol use disorder, and practical guidance.
Read the full guide →
Results & Expectations
Sep 1, 2025 • 10 min read
The STEP-4 withdrawal trial found that people who stopped semaglutide regained about two-thirds of their lost weight within a year. This isn't a willpower failure—it's biology. We explain why regain happens, what metabolic changes reverse, what you can do to protect your results, and how obesity medicine is rethinking GLP-1s as long-term treatment rather than a short-term fix.
Read the full guide →
Eligibility
Sep 1, 2025 • 10 min read
In the STEP-1 trial, 84% of prediabetic semaglutide patients reverted to normal blood sugar. In SURMOUNT-1, 95% of prediabetic tirzepatide patients achieved normoglycemia. These numbers dwarf the Diabetes Prevention Program results. We explain how GLP-1s prevent diabetes progression, how prediabetes qualifies you for Wegovy, and the insurance landscape for this indication.
Read the full guide →
Lifestyle
Sep 1, 2025 • 11 min read
You're eating significantly less on Ozempic—which means every calorie counts more. High protein intake (1.2–1.6g/kg) is critical to prevent muscle loss. High-fat foods worsen nausea. Liquid calories bypass satiety. We cover the best protein sources, what to avoid on injection day, practical meal structure, and the micronutrient gaps to watch for on reduced calorie intake.
Read the full guide →